Statins and the risk of gynecological cancer: a Norwegian population-based cohort study
International Journal of Epidemiology · 2025
DOI: 10.1093/ije/dyaf133 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Epidemiology, 2025. Verfasst von Leif Lukas Löfling und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Council of Norway.
Abstract (Originalsprache)
Background
Endometrial, ovarian, and cervical cancers are the most common gynecological cancers, with 1.4 million diagnoses worldwide in 2022. Statins are widely used for cardiovascular conditions and have been studied for their association with gynecological cancer risk, but results to date have been inconclusive.
Methods
We conducted a population-based cohort study including data from the Norwegian Prescription Database and the Cancer Registry of Norway, and followed women aged ≥50 years from 2004 to 2018. We examined the association between statin use overall and by type (lipophilic, hydrophilic), and the risk of endometrial, ovarian, and cervical cancers overall and by age groups and histologic subgroup using Cox proportional hazard models.
Results
The cohort study included 1 083 629 women. During a median follow-up of 11.6 years, 334 582 (31%) used statins at least once. There were 7709 cases of endometrial, 4415 cases of ovarian, and 1603 cases of cervical cancers. Statin use was associated with reduced risk of endometrial cancer [current use hazard ratio (HR) = 0.90, 95% confidence interval (CI): 0.85–0.96; past use HR = 0.79, 95% CI: 0.71–0.88]; associations were observed only for the lipophilic statins, and with similar associations by age groups and for type I and II endometrial cancer. No consistent associations were found for ovarian or cervical cancers. We found no trends for cumulative defined daily doses of current use or time since cessation for any cancer type.
Conclusion
Statin use was associated with a reduced risk of endometrial cancer but not with the risk of ovarian cancer or cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
- Section for Epidemiology, Norwegian Veterinary Institute, Ås, Norway.
- Section for Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
- Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
ORCID-Profile: Renée Turzanski Fortner
Förderung
- Research Council of Norway
Zitieren
APA
Löfling, L. L., Støer, N. C., Botteri, E., & Fortner, R. T. (2025). Statins and the risk of gynecological cancer: a Norwegian population-based cohort study. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyaf133
Vancouver
Löfling LL, Støer NC, Botteri E, Fortner RT. Statins and the risk of gynecological cancer: a Norwegian population-based cohort study. International Journal of Epidemiology. 2025. doi:10.1093/ije/dyaf133
BibTeX
@article{Lfling2025,
author = {Löfling, Leif Lukas and Støer, Nathalie C and Botteri, Edoardo and Fortner, Renée Turzanski},
title = {Statins and the risk of gynecological cancer: a Norwegian population-based cohort study},
journal = {International Journal of Epidemiology},
year = {2025},
doi = {10.1093/ije/dyaf133}
}
EUVIMED